SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, has appointed veteran medical technology finance executive Sarah M. Romano as chief financial officer, effective August 3, 2026. The appointment adds public-company financial and capital markets experience as the company continues its global expansion and advances regulatory initiatives.
Romano brings more than two decades of experience in public-company finance, capital markets, and medical technology, having raised more than $100 million during her career. She joins SS Innovations after serving as CFO at Vicarious Surgical, another robotic surgical technology developer, where she oversaw financial and operational initiatives designed to reduce cash burn, strengthen the company’s balance sheet and support growth.
The leadership addition comes at a pivotal time for SS Innovations, which is pursuing broader commercialization of its SSi Mantra surgical robotic platform while continuing preparations for U.S. Food and Drug Administration review. The company is actively expanding internationally, recently graduating the inaugural class of its SS International Centre for Robotics Surgery (“SSICRS”) cardiac robotic surgery training program. The program welcomed 33 healthcare professionals from seven countries, underscoring the company's emphasis on surgeon education alongside technology deployment.
For business leaders and technology executives, the appointment signals SS Innovations' strategic focus on financial discipline and regulatory readiness. The company's pursuit of FDA clearance for the SSi Mantra system could position it to compete in the U.S. surgical robotics market, currently dominated by Intuitive Surgical's da Vinci system. The global surgical robotics market is projected to grow significantly, driven by demand for minimally invasive procedures and technological advancements. SS Innovations' expansion of training programs abroad indicates a strategy to build a skilled user base ahead of potential U.S. market entry.
The company's recent training initiative, which drew healthcare professionals from seven countries, highlights its commitment to establishing a global footprint. By investing in surgeon education, SS Innovations aims to reduce adoption barriers and accelerate clinical integration of its technology. This approach could be crucial for gaining traction in markets where robotic surgery is still emerging.
For investors, Romano's track record in capital markets and financial restructuring may provide confidence in the company's ability to manage cash flow and secure funding for regulatory and commercialization efforts. Her experience at Vicarious Surgical in reducing cash burn suggests a focus on operational efficiency, which could be critical as SS Innovations navigates the costly FDA approval process.
The broader implications for the industry are significant. If SS Innovations secures FDA clearance, it could introduce competition to the U.S. robotic surgery market, potentially driving down costs and expanding access to advanced surgical technologies. The company's emphasis on training also addresses a key barrier to adoption: the need for specialized surgeon skills. As robotic surgery becomes more prevalent, companies that invest in comprehensive education programs may gain a competitive edge.
More details on the company's strategic direction are available in its newsroom at https://ibn.fm/SSII. Information regarding FDA review preparations can be found at https://nnw.fm/yY4UM.
